Make an Inquiry
Accelerating Uveitis Drug Development

Uveitis presents a significant therapeutic challenge, often leading to vision impairment and complex clinical management. Protheragen stands at the forefront of preclinical drug development, offering specialized expertise in advancing novel therapeutics for Uveitis. Leveraging a robust portfolio of preclinical capabilities, Protheragen supports partners from target validation through IND-enabling studies, ensuring a seamless and scientifically rigorous pathway to clinical development. With deep scientific expertise and access to advanced technology platforms, Protheragen delivers comprehensive solutions tailored to the unique pathophysiology of Uveitis. The company’s integrated approach encompasses in vitro and in vivo modeling, pharmacokinetics, pharmacodynamics, and safety assessments, all conducted in strict adherence to global regulatory standards. Protheragen’s commitment to quality and compliance minimizes risk and accelerates timelines, empowering clients to navigate the complexities of Uveitis drug development with confidence. Driven by innovation and a dedication to scientific excellence, Protheragen is committed to expediting the discovery and development of transformative therapies for Uveitis. By partnering with Protheragen, organizations gain a trusted ally focused on delivering therapeutic breakthroughs that address critical unmet medical needs in ophthalmology.

What is UveitisTargets for UveitisDrug Discovery and Development ServicesWhy Choose Us

What is Uveitis

Uveitis refers to a diverse group of inflammatory diseases affecting the uveal tract of the eye, which includes the iris, ciliary body, and choroid, and may extend to adjacent structures such as the retina and optic nerve. The condition can result from infectious agents, immune-mediated mechanisms, or serve as a manifestation of systemic autoimmune diseases; however, many cases remain idiopathic. Pathophysiologically, uveitis involves disruption of the blood-ocular barrier, immune cell infiltration, and the release of inflammatory mediators, leading to tissue damage and a significant risk of vision loss. Uveitis is a major cause of visual impairment worldwide, particularly among adults between 20 and 50 years of age. Clinically, uveitis presents with symptoms such as ocular pain, redness, photophobia, floaters, and decreased vision, with manifestations varying by the anatomic location—anterior, intermediate, posterior, or panuveitis. Diagnosis relies on a thorough ophthalmic examination, including slit-lamp biomicroscopy, fundus evaluation, and imaging techniques like OCT and angiography, supported by targeted laboratory investigations to identify underlying causes. Treatment is tailored to disease severity and etiology, with options including corticosteroids (topical, systemic, or intravitreal implants), immunosuppressive agents like ciclosporin, and biologic therapies such as adalimumab for non-infectious forms. Early recognition and appropriate management are essential to prevent irreversible complications and preserve vision.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
adalimumab
adalimumab; adalimumab-aaty
adalimumab; adalimumab-bwwd
adalimumab; adalimumab-adaz
adalimumab; adalimumab-atto
adalimumab; adalimumab-fkjp
dexamethasone intravitreal implant
adalimumab (Rec INN; USAN) 331731-18-1
img-59865-13-3-ciclosporin-rec-inncyclosporincyclosporin-acyclosp ciclosporin (Rec INN); cyclosporin; cyclosporin A; cyclosporine; cyclosporine A 59865-13-3 C62 H111 N11 O12 1202.611
img-67-73-2-fluocinolone-acetonide-rec-inn-usan-ban-jansinalar fluocinolone acetonide (Rec INN; USAN; BAN; JAN); sinalar; synandone 67-73-2 C24 H30 F2 O6 452.488

Learn More

Targets for Uveitis

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
insulin INS
protein phosphatase 3 catalytic subunit gamma PPP3CC
protein phosphatase 3 catalytic subunit beta PPP3CB
Protein Phosphatase 2B
protein phosphatase 3 regulatory subunit B, alpha PPP3R1
peptidylprolyl isomerase D PPID
nuclear receptor subfamily 3 group C member 1 NR3C1
peptidylprolyl isomerase A PPIA
tumor necrosis factor TNF
protein phosphatase 3 regulatory subunit B, beta PPP3R2

Uveitis is driven by a complex network of immune mediators and signaling pathways, with several molecular targets playing pivotal roles in disease pathogenesis. Key among these are pro-inflammatory cytokines such as interleukin 1 beta (IL1B) and tumor necrosis factor (TNF), which orchestrate leukocyte recruitment, endothelial activation, and the amplification of ocular inflammation. Co-stimulatory molecules like CD86 further facilitate T cell activation, breaking ocular immune privilege and sustaining autoimmune responses. Intracellular kinases including Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and tyrosine kinase 2 (TYK2) are integral to cytokine signaling, promoting pathogenic T helper cell differentiation and perpetuating inflammation via the JAK/STAT pathway. Additionally, the nuclear receptor NR3C1, encoding the glucocorticoid receptor, is essential for mediating endogenous and therapeutic anti-inflammatory effects.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates uveitis drug discovery by providing comprehensive screening and characterization of candidate therapeutics. Utilizing advanced biochemical and cellular assays—including ATP, chemiluminescent, peptide substrate, and surface plasmon resonance methods—we evaluate activity against key inflammatory targets such as JAK1, JAK2, TYK2, PKCθ, TNF, and PPIA. We deliver quantitative pharmacological parameters (IC-50, EC-50, Kd) to assess potency, efficacy, and target engagement. Our tailored platforms enable robust, sensitive, and reliable data generation, supporting effective candidate prioritization and mechanism-of-action studies for the development of novel uveitis therapies.

Janus Kinase 1 Janus Kinase 2
Peptidylprolyl Isomerase A Protein Kinase C Theta
Tumor Necrosis Factor Tyrosine Kinase 2

Learn More

Why Choose Us

Choosing Protheragen means partnering with a company that possesses specialized expertise in Uveitis research and drug development. Our dedicated teams bring years of experience in the field, combining scientific excellence with a deep understanding of the complexities involved in developing effective therapeutics for Uveitis. At Protheragen, we utilize advanced technology platforms that enable us to accelerate drug discovery and optimize preclinical development processes. Our proven track record in delivering reliable preclinical drug development services demonstrates our commitment to meeting client expectations and advancing therapeutic solutions. We adhere to the highest quality standards and maintain strict regulatory compliance throughout every stage of development, ensuring that our work meets both industry and global requirements. Above all, Protheragen is committed to making a meaningful difference in the lives of patients affected by Uveitis. We strive to push the boundaries of innovation and bring new, effective treatments to market with professionalism and integrity. By choosing Protheragen, you are selecting a trusted partner dedicated to advancing Uveitis therapeutics with reliability, expertise, and a genuine commitment to quality.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing drugs for Uveitis?

A: Uveitis presents unique preclinical research challenges, including the need for robust and translational animal models that accurately mimic human disease pathology. Inflammation in the uveal tract can have diverse etiologies and manifestations, making model selection and validation critical. Additionally, evaluating drug delivery to ocular tissues and achieving therapeutic concentrations without systemic toxicity requires specialized expertise. Our team addresses these challenges by employing validated models, advanced imaging, and pharmacokinetic assessments tailored for ocular drug development.

Q: What are the key regulatory considerations for preclinical development of Uveitis therapies?

A: Regulatory agencies, such as the FDA and EMA, require comprehensive preclinical data demonstrating safety, pharmacology, and proof-of-concept efficacy in relevant models before advancing to clinical studies. For Uveitis, this includes ocular toxicity studies, biodistribution analysis, and assessment of potential off-target effects. We support clients by designing regulatory-compliant preclinical programs, generating high-quality data, and preparing documentation for IND/CTA submissions, ensuring alignment with current regulatory expectations.

Q: What technical aspects are critical in preclinical Uveitis research?

A: Critical technical aspects include the selection and validation of animal models (such as EAU in rodents), use of advanced ocular imaging (OCT, fluorescein angiography), and quantification of inflammatory biomarkers in ocular tissues. In addition, precise dosing and drug delivery methods—such as intravitreal injection or sustained-release formulations—are essential. Our facilities are equipped with state-of-the-art imaging and analytical platforms, and our scientists have extensive experience in ocular pharmacology and immunology.

Q: What are the typical timeline and cost considerations for preclinical Uveitis drug development?

A: Preclinical development timelines for Uveitis therapies typically range from 12 to 24 months, depending on the complexity of the studies and regulatory requirements. Costs vary based on the number of studies, types of models, and analytical endpoints required, but can range from several hundred thousand to over a million USD. We offer flexible, modular service packages and transparent cost estimates, enabling clients to plan and allocate resources effectively while maintaining high scientific and regulatory standards.

Q: What are the key success factors in preclinical drug development for Uveitis?

A: Success in preclinical Uveitis drug development hinges on several factors: selecting the right disease models, designing robust and reproducible studies, ensuring regulatory compliance, and integrating multidisciplinary expertise in immunology, pharmacology, and ocular biology. Early identification and mitigation of potential safety or efficacy issues are also crucial. Our company’s integrated approach, experienced team, and commitment to scientific excellence help maximize the probability of success for our clients’ Uveitis drug candidates.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2025 Protheragen. All rights reserved.